HR Low-Positive/HER2-Negative Breast Neoplasms
1 clinical trials · Condition
◉ Watch HR Low-Positive/HER2-Negative Breast Neoplasms
| Record | Firm | Date |
|---|---|---|
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (NCT06966700) | Merck Sharp & Dohme LLC | 2025-06-30 |
Track HR Low-Positive/HER2-Negative Breast Neoplasms automatically
Every clearance here is in the API, with alerts when new ones post.